Anne Sophie V M Van den Heerik, Cathalijne C B Post, Marie A D Haverkort, Nienke Kuijsters, Stefan Kommoss, Friederike L A Koppe, Marlies E Nowee, Henrike Westerveld, Maria A A De Jong, Filip Frühauf, Jeltsje S Cnossen, Jan Willem M Mens, Jannet C Beukema, Cyrus Chargari, Charles Gillham, Dorine S J Tseng, Katrien Vandecasteele, Karen Verhoeven-Adema, Hans W Nijman, Remi A Nout, Bastiaan G Wortman, Stephanie M De Boer, Hein Putter, Vincent T H B M Smit, Carien L Creutzberg, Nanda Horeweg
{"title":"Toxicity, health-related quality of life and sexuality after molecular profile-based adjuvant treatment in high-intermediate risk endometrial cancer, PORTEC-4a.","authors":"Anne Sophie V M Van den Heerik, Cathalijne C B Post, Marie A D Haverkort, Nienke Kuijsters, Stefan Kommoss, Friederike L A Koppe, Marlies E Nowee, Henrike Westerveld, Maria A A De Jong, Filip Frühauf, Jeltsje S Cnossen, Jan Willem M Mens, Jannet C Beukema, Cyrus Chargari, Charles Gillham, Dorine S J Tseng, Katrien Vandecasteele, Karen Verhoeven-Adema, Hans W Nijman, Remi A Nout, Bastiaan G Wortman, Stephanie M De Boer, Hein Putter, Vincent T H B M Smit, Carien L Creutzberg, Nanda Horeweg","doi":"10.1038/s41416-026-03642-4","DOIUrl":"https://doi.org/10.1038/s41416-026-03642-4","url":null,"abstract":"<p><strong>Background: </strong>PORTEC-4a was the first to incorporate molecular-integrated profile-guided adjuvant treatment in early-stage high-intermediate-risk endometrial cancer (EC), demonstrating non-inferiority. Here, adverse events (AE), health-related quality of life (HRQoL) and sexual health are reported.</p><p><strong>Methods: </strong>564 patients were randomised to molecular-based adjuvant treatment (n = 367) or standard vaginal brachytherapy (VBT, n = 197). In the molecular-profile arm, patients underwent observation, VBT or pelvic radiotherapy according to molecular-integrated profile. HRQoL and sexual functioning were assessed with EORTC QLQ-C30 and EN24 modules and compared with age-matched normative data.</p><p><strong>Results: </strong>Median follow-up was 58.1 months; 523 (92.7%) patients were evaluable. Grade 1-2 AEs were less frequent in the molecular-profile arm at treatment completion compared with the standard arm (28.3% vs. 45.2%, p < 0.01), without differences in grade 3-4 AEs (p = 0.46). Throughout follow-up, treatment-related grade 3-4 AEs were rare (1% vs. 2%). HRQoL remained comparable to normative data over time. Sexual interest/activity was similar between arms, but lower than normative values. 75.5% of patients reported ≥1 reason for sexual inactivity; disease-related sexual inactivity decreased from 24.2% to 9.2% at 3 years.</p><p><strong>Conclusion: </strong>Molecular-guided adjuvant treatment for patients with high-intermediate riskEC is associated with low toxicity, preserved HRQoL and slightly reduced sexual activity due to personal factors (no partner, sex not important in their relationship or partner-related medical issues) rather than their own illness.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Philipp Heumann, Juan C Rosas, Miguel E Aguado-Barrera, David Azria, Axel Benner, Erik Briers, Renée Bultijnck, Ananya Choudhury, Antonio Gómez-Caamaño, Rudolf Kaaks, Maarten Lambrecht, Tiziana Rancati, Barry S Rosenstein, Dirk De Ruysscher, Martina E Schmidt, Susanne Singer, Elena Sperk, Hilary Stobart, Ana Vega, Liv Veldeman, Tim Ward, Adam Webb, Catharine M West, Jenny Chang-Claude, Christopher J Talbot, Tim Rattay, Petra Seibold
{"title":"Long-term fatigue dimensions in the Multidimensional Fatigue Inventory (MFI) up to five years after radiotherapy and their trajectories in men diagnosed with non-metastatic prostate cancer in the international REQUITE study.","authors":"Philipp Heumann, Juan C Rosas, Miguel E Aguado-Barrera, David Azria, Axel Benner, Erik Briers, Renée Bultijnck, Ananya Choudhury, Antonio Gómez-Caamaño, Rudolf Kaaks, Maarten Lambrecht, Tiziana Rancati, Barry S Rosenstein, Dirk De Ruysscher, Martina E Schmidt, Susanne Singer, Elena Sperk, Hilary Stobart, Ana Vega, Liv Veldeman, Tim Ward, Adam Webb, Catharine M West, Jenny Chang-Claude, Christopher J Talbot, Tim Rattay, Petra Seibold","doi":"10.1038/s41416-026-03626-4","DOIUrl":"10.1038/s41416-026-03626-4","url":null,"abstract":"<p><strong>Background: </strong>Fatigue is a common, multidimensional symptom in cancer patients. Little is known about fatigue dimensions and their trajectories in prostate cancer (PCa).</p><p><strong>Methods: </strong>Using the Multidimensional Fatigue Inventory (MFI), 1097 men treated with radiotherapy for non-metastatic PCa (2014-2016) prospectively reported fatigue up to five years later. Prevalent fatigue was defined as scores ≥75th percentile in men aged ≥60 years in a German general population sample. Pre-radiotherapy patient characteristics were examined for their associations with general fatigue, physical fatigue, mental fatigue, reduced activity, and reduced motivation two years later using logistic regression models. Fatigue trajectories up to two years post-radiotherapy were explored using latent class growth analysis and multinomial regression.</p><p><strong>Results: </strong>About 72% (785/1097) of patients reported being fatigued for at least one dimension in the MFI from before the start of radiotherapy up to five years later, with 45% (367/816) being fatigued two years post-radiotherapy. Pre-radiotherapy fatigue level (OR: 4.7-9.0), depression (OR: 2.5), diabetes (OR: 1.8-2.2), hypertension (OR: 1.6-1.8), and BMI (OR: 1.8-2.2) were statistically significant predictors of long-term fatigue two years post-radiotherapy across dimensions. Depression, BMI, and pelvic radiotherapy were associated with experiencing a high fatigue trajectory.</p><p><strong>Conclusions: </strong>Early fatigue assessments, in addition to self-reported comorbidities and BMI, showed additional benefits beyond symptom detection by providing prognostic value for poorer long-term fatigue outcomes. Multidimensional fatigue assessments could guide tailored symptom management strategies, targeting specific dimensions to address associated impairments in quality of life and functioning.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qiulin Yan, Hui Ren, Haiying Xu, Xuehan Ma, Yuanqing Li, Qiurong Liu, Yi Yang, Qingbo Liu, Guo-Dong Yao, Shao-Jiang Song
{"title":"SKP2-mediated CDK4 selective degradation contributes to SCP-7e-induced cell death of non-small cell lung cancer.","authors":"Qiulin Yan, Hui Ren, Haiying Xu, Xuehan Ma, Yuanqing Li, Qiurong Liu, Yi Yang, Qingbo Liu, Guo-Dong Yao, Shao-Jiang Song","doi":"10.1038/s41416-026-03653-1","DOIUrl":"https://doi.org/10.1038/s41416-026-03653-1","url":null,"abstract":"<p><strong>Background: </strong>CDK4/6 are key cell-cycle regulators. CDK4/6 inhibitors encounter obstacles from therapeutic resistance and haematological toxicity, primarily due to potent CDK6 inhibition. Developing selective inhibitors against specific CDK members could address these limitations, but faces challenges from the high homology of ATP-binding sites.</p><p><strong>Methods: </strong>SCP-7 is a sesquiterpene lactone derivative with potent anti-non-small cell lung cancer (NSCLC) activity. Carbamate modification yields the optimised analogue SCP-7e. Biotinylated probe-based target fishing, MCODE analysis, DARTS, CETSA, SPR, circular dichroism and tryptophan fluorescence quenching analysis identified CDK4 as the target. The binding site on CDK4 was determined by LC-MS/MS, site-directed mutagenesis and covalent molecular docking. Co-immunoprecipitation was employed to elucidate the molecular mechanisms.</p><p><strong>Results: </strong>SCP-7 and SCP-7e selectively bind to CDK4, excluding CDK6 and promote the ubiquitin-proteasome degradation of CDK4. SCP-7e exhibits enhanced metabolic stability, superior in vivo anti-NSCLC activity, higher CDK4 binding affinity and greater degradation efficiency than SCP-7. Mechanistically, SCP-7e covalently binds to Cys78, a residue located outside the ATP-binding pocket of CDK4, thereby sterically blocking CDK4-cyclin D1 interaction and inducing SKP2-mediated degradation of CDK4.</p><p><strong>Conclusions: </strong>This study identified Cys78 as a novel druggable site on CDK4 and provided a selective CDK4 degrader, advancing next-generation selective CDK inhibitors.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A Tannapfel, K Engeland, L Weinans, A Katalinic, J Hauss, J Mössner, Ch Wittekind
{"title":"Editorial Expression of Concern: Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver.","authors":"A Tannapfel, K Engeland, L Weinans, A Katalinic, J Hauss, J Mössner, Ch Wittekind","doi":"10.1038/s41416-026-03651-3","DOIUrl":"https://doi.org/10.1038/s41416-026-03651-3","url":null,"abstract":"","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Benzeer Siddique, Thomas Duffy, Natalie Gil, Andrew Prentice, Sarah Marshall, Natasha Djedovic, Abhinav Sundriyal, Michael Lewis, Josephine Ruwende, Ghalia Kayal, Aradhna Kaushal, Yasemin Hirst, Stephen Duffy, Christian von Wagner, Robert S Kerrison
{"title":"Which is more effective at improving uptake of bowel cancer screening: text message reminders or patient navigation? Results from a three-arm RCT.","authors":"Benzeer Siddique, Thomas Duffy, Natalie Gil, Andrew Prentice, Sarah Marshall, Natasha Djedovic, Abhinav Sundriyal, Michael Lewis, Josephine Ruwende, Ghalia Kayal, Aradhna Kaushal, Yasemin Hirst, Stephen Duffy, Christian von Wagner, Robert S Kerrison","doi":"10.1038/s41416-026-03645-1","DOIUrl":"https://doi.org/10.1038/s41416-026-03645-1","url":null,"abstract":"<p><strong>Background: </strong>Text message reminders (TMRs) and patient navigation (PN) increase bowel cancer screening uptake. To date, no studies have directly compared these interventions with one another.</p><p><strong>Methods: </strong>We conducted a three-arm randomised controlled trial with individuals, in London, who had not completed bowel cancer screening within 18 weeks of invitation. Participants were randomised to receive no reminder (usual care), TMRs at 19, 21, 23 and 25 weeks, or a TMR at 19 weeks, with telephone PN at 21, 23 and 25 weeks. The primary outcome was participation within 26 weeks of invitation. Differences were assessed using logistic regression.</p><p><strong>Results: </strong>On an intention-to-treat basis (n = 3129), uptake was higher in the TMR and PN groups, compared with usual care (6.5% vs. 2.0%, p < 0.001; 7.5% vs. 2.0%, p < 0.001). There was no significant difference between TMR and PN groups. In the per-protocol analysis (n = 2294), uptake was significantly higher in the PN group than the TMR group (8.6 vs. 12.6%, p < 0.025). Subgroup analyses revealed telephone PN was significantly more effective than TMRs for men, specifically (14.5% vs. 6.7%, p < 0.001).</p><p><strong>Conclusions: </strong>While TMRs are no more effective than PN in general, implementing PN could help reduce disparities in uptake between men and women.</p><p><strong>Trial registration: </strong>ISRCTN17245519.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Philipp Heumann, Juan C Rosas, Miguel E Aguado-Barrera, David Azria, Axel Benner, Erik Briers, Renée Bultijnck, Ananya Choudhury, Antonio Gómez-Caamaño, Rudolf Kaaks, Maarten Lambrecht, Tiziana Rancati, Barry S Rosenstein, Dirk De Ruysscher, Martina E Schmidt, Susanne Singer, Elena Sperk, Hilary Stobart, Ana Vega, Liv Veldeman, Tim Ward, Adam Webb, Catharine M West, Jenny Chang-Claude, Christopher J Talbot, Tim Rattay, Petra Seibold
{"title":"Long-term fatigue based on the EORTC QLQ-C30 up to five years after radiotherapy and its trajectories in men diagnosed with non-metastatic prostate cancer in the international REQUITE study.","authors":"Philipp Heumann, Juan C Rosas, Miguel E Aguado-Barrera, David Azria, Axel Benner, Erik Briers, Renée Bultijnck, Ananya Choudhury, Antonio Gómez-Caamaño, Rudolf Kaaks, Maarten Lambrecht, Tiziana Rancati, Barry S Rosenstein, Dirk De Ruysscher, Martina E Schmidt, Susanne Singer, Elena Sperk, Hilary Stobart, Ana Vega, Liv Veldeman, Tim Ward, Adam Webb, Catharine M West, Jenny Chang-Claude, Christopher J Talbot, Tim Rattay, Petra Seibold","doi":"10.1038/s41416-026-03644-2","DOIUrl":"https://doi.org/10.1038/s41416-026-03644-2","url":null,"abstract":"<p><strong>Background: </strong>Fatigue is a common symptom in cancer patients associated with impaired quality of life (QoL). Little is known about long-term fatigue trajectories in prostate cancer (PCa) patients.</p><p><strong>Methods: </strong>Using the European Organisation for Research and Treatment of Cancer Quality of Life Group Core Questionnaire (EORTC QLQ-C30), 1758 men treated with radiotherapy (2014-2016) for non-metastatic PCa prospectively reported fatigue up to five years later. Associations between pre-radiotherapy characteristics and clinically important fatigue (Score: ≥39/100) two years post-radiotherapy were investigated using logistic regression. Fatigue trajectories were explored using latent class growth analysis and multinomial regression.</p><p><strong>Results: </strong>About 35% (608/1758) of patients experienced clinically important fatigue at least once from the start of radiotherapy up to five years later. Two years post-radiotherapy, 14% of patients reported fatigue, which was associated with pre-radiotherapy fatigue level (OR: 8.67), self-reported diabetes (OR: 1.94), BMI (OR: 1.07), and age (OR: 1.03). Long-term fatigue was strongly linked to pain, insomnia, pelvic symptoms, functional impairments, and reduced QoL. Four fatigue trajectories were identified, characterised by low (45%), moderate (42%), elevated and decreasing (8%), and (6%) increasing mean fatigue levels. Diabetes was associated with a 6 percentage point increase in the probability of experiencing an increasing fatigue trajectory.</p><p><strong>Conclusions: </strong>The findings emphasise the need for early identification of PCa patients susceptible to long-term fatigue. PCa patients with elevated pre-radiotherapy fatigue levels and diabetes may require closer monitoring in risk-stratified aftercare programmes.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maria Olivia Santos, Mary E Dotson, Eliza Steinberg, Jeniffer Ambaka, Megan Huchko, Nimmi Ramanujam
{"title":"A randomized clinical trial comparing visual inspection with acetic acid (VIA) to Pocket Colposcopy for the triage of HPV+ women living with HIV in Kisumu, Kenya.","authors":"Maria Olivia Santos, Mary E Dotson, Eliza Steinberg, Jeniffer Ambaka, Megan Huchko, Nimmi Ramanujam","doi":"10.1038/s41416-026-03609-5","DOIUrl":"https://doi.org/10.1038/s41416-026-03609-5","url":null,"abstract":"<p><strong>Objective: </strong>The WHO recommends a \"screen, triage, treat\" approach for cervical cancer screening for Women Living with HIV (WLWH) in resource-limited settings, with HPV testing preferred for screening. We sought to compare Visual Assessment with Acetic Acid (VIA) assisted with the Pocket Colposcope to naked eye VIA for triage of HPV + WLWH.</p><p><strong>Methods: </strong>In a randomized clinical trial across six clinics in Kisumu, Kenya (November 2022 to June 2023), HPV + WLWH were randomized to VIA or Pocket colposcopy. Exam positivity was determined by presence of aceto-white epithelium (AWE); biopsies were taken from AWE or randomly if negative. Diagnostic accuracy was confirmed with pathology. Providers and participants completed post-exam surveys.</p><p><strong>Findings: </strong>Positive exam rates were 17.3% (VIA) and 14.3% (Pocket). Overall, CIN2/3 prevalence was 15.4% (12.2% VIA, 18.8% Pocket). Sensitivity, specificity, and negative predictive value were similar between arms. However, the Pocket showed a non-significant higher positive predictive value (37.5% vs 20.6%). Both providers and patients found the Pocket acceptable for triage.</p><p><strong>Conclusion: </strong>The Pocket colposcope detected more treatable disease and reduced overtreatment. This study shows the Pocket colposcope is a feasible, lower-cost device that could facilitate biopsy confirmation, increase provider training, improve patient education, and enable remote diagnosis.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Conformational heterogeneity: a fundamental mechanism of adaptive phenotypic plasticity and therapeutic resistance.","authors":"Ruth Nussinov, Hyunbum Jang","doi":"10.1038/s41416-026-03649-x","DOIUrl":"https://doi.org/10.1038/s41416-026-03649-x","url":null,"abstract":"<p><p>Specific genetic mutations serve as clues to cancer emergence. However, non-genetic cell state shift mechanisms-such as the epithelial-to-mesenchymal transition (EMT)-drive swift, reversible drug tolerance and metastasis. Unlike the slow process of acquiring mutations, this plasticity allows rapid, drug-tolerant cells to revert to previous states upon withdrawal of the drug, thereby driving pharmacological resistance. Insight into the evolution of cell states in cancer is critical for optimizing drug regimens. Here we propose dynamic conformational heterogeneity as an untapped fundamental driver of adaptive resistance. Proteins do not function as simple binary switches; rather, they exist as dynamic ensembles. Cancer arises when their conformational distribution shifts permanently towards an active state. Drugs operate by selecting specific (oncogenic) 3D conformer shapes and reverse-shifting the population back to a stabilized inactive state. Epigenetic dysregulation in cancer cells amplifies expression levels of these proteins, shifting the ensemble toward the oncogenic state. The increased abundance of the active state saturates the networks, overcoming feedback controls. We propose that effectively countering cancer evolution requires drug combinations that target oncogenic conformations at both molecular and systems levels, including adaptive phenotypic plasticity factors, shifting focus from individual static targets to dynamic population states.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":7.8,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}